Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 1999

View Archived Issues

Genzyme Molecular Oncology significantly strengthens pipeline with acquisition

Barr Laboratories highlights proprietary pipeline at investors conference

Medeva confirms merger negotiations

U Penn researchers identify new target for treatment of erectile dysfunction

New type III antiarrhythmic marketed in Japan

ATL launches Pollinex Quattro allergy vaccines incorporating MPL in Germany

Glaxo Wellcome outlines key future products at NYC conference

Naturally occurring antiapoptotic compounds disclosed by Shionogi

Corvas begins second phase II trial for anticoagulant rNAPc2

AxyS Pharmaceuticals licenses rights to Signal's SERM-beta compounds for cancer indications

New polyaromatic compounds for herpesvirus infections designed at P&U

First once-daily morphine approved in Japan

Inhibitex receives clearance to begin clinical trials of S. aureus prophylactic

Alosetron relieves pain and improves bowel function in women with IBS

Guilford claims new NAALADase inhibitors for glutamate abnormalities, prostate disorders

SkyePharma acquires Hyal's assets

Novel class of Ampakines described by U.S. university researchers

CGS-35066: potent and specific ECE inhibitor presented at ET-6

Merz concludes two phase III trials of memantine in vascular dementia

Harvard team succeeds in promoting angiogenesis in coronary arteries

Kos Pharmaceuticals receives U.S. approval for Niaspan in dyslipidemia

Risk of sitafloxacin-resistant mutants is expected to be low

Celltech Chiroscience development partner files for FDA approval of AML treatment

AHP describes novel serotonergic agents for depression and anxiety

3-D's new protease (thrombin) inhibitors

Coumarin inhibitors of DNA gyrase in development at HMR

Candidate treatment for atopic dermatitis presented at Japanese congress

Celecoxib in FAP: results of clinical trial discussed at ACG

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...